| Literature DB >> 23410976 |
Bryan W Day1, Brett W Stringer, Fares Al-Ejeh, Michael J Ting, John Wilson, Kathleen S Ensbey, Paul R Jamieson, Zara C Bruce, Yi Chieh Lim, Carolin Offenhäuser, Sara Charmsaz, Leanne T Cooper, Jennifer K Ellacott, Angus Harding, Lucie Leveque, Po Inglis, Suzanne Allan, David G Walker, Martin Lackmann, Geoffrey Osborne, Kum Kum Khanna, Brent A Reynolds, Jason D Lickliter, Andrew W Boyd.
Abstract
Significant endeavor has been applied to identify functional therapeutic targets in glioblastoma (GBM) to halt the growth of this aggressive cancer. We show that the receptor tyrosine kinase EphA3 is frequently overexpressed in GBM and, in particular, in the most aggressive mesenchymal subtype. Importantly, EphA3 is highly expressed on the tumor-initiating cell population in glioma and appears critically involved in maintaining tumor cells in a less differentiated state by modulating mitogen-activated protein kinase signaling. EphA3 knockdown or depletion of EphA3-positive tumor cells reduced tumorigenic potential to a degree comparable to treatment with a therapeutic radiolabelled EphA3-specific monoclonal antibody. These results identify EphA3 as a functional, targetable receptor in GBM.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23410976 DOI： 10.1016/j.ccr.2013.01.007
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743